Navigation Links
92 Medicines and Vaccines now in Development for HIV/AIDS
Date:11/20/2007

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Pharmaceutical researchers are testing 92 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 20th anniversary of "World AIDS Day" -- a global awareness campaign that originated at the 1988 World Summit of Ministers of Health on Programmes for AIDS Prevention.

"We are greatly encouraged by the new, critically-important medicines and vaccines in development to treat and prevent HIV infection," says PhRMA President and CEO Billy Tauzin. "Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients."

The report found that of the 92 products in development, researchers are studying 20 vaccines and 46 antivirals. These drugs are either in human clinical trials or await approval by the U.S. Food and Drug Administration.

The report also lists 30 medicines to treat HIV/AIDS that have been approved since the virus that causes AIDS was first identified more than 20 years ago. The first such medicine was developed in 1987, just four years after the HIV virus was identified. The increased availability and utilization of newer prescription medicines has helped to reduce the U.S. death rate from AIDS substantially in recent years, according to government statistics.

Despite that progress, AIDS remains a devastating and growing worldwide health problem in developing countries, particularly in sub-Saharan Africa, China, India and the Russian Federation. According to the Joint United Nations Programme on HIV/AIDS, an estimated 32.7 million people worldwide lived with HIV at the end of 2006.

This year, that figure grew to an estimated 33.2 million people living with HIV, with an estimated 2.1 million people newly infected in 2007.

From 2000 to 2006, A
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
2. Concentra Offers Flu Vaccines to Keep America Working
3. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Promising Cystic Fibrosis Compound on Track for Development
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... NEW ORLEANS, Dec. 6 Amgen Inc. ... three studies on the safety and efficacy of ... (MDS). MDS is a pre-leukemic condition in which ... are unable to mature normally, thereby limiting their ... can lead to low platelet counts. The results ...
(Date:12/4/2009)... A simple, inexpensive computer tool that measures volume ... lungs picked up by a CT scanner can rule ... doctors to diagnose true cancers with fewer, less expensive ... ,, The new diagnostic guidelines are described in a ...
(Date:12/4/2009)... are Transported ,, PHILADELPHIA, Dec. 4 ... American Red Cross are hard at work educating the ... that could potentially put Philadelphia,s blood supply at risk. ... set up a picket line yesterday when their issues ...
Breaking Medicine Technology:Nplate(R) Data From MDS Studies Presented at ASH 2Nplate(R) Data From MDS Studies Presented at ASH 3Nplate(R) Data From MDS Studies Presented at ASH 4Nplate(R) Data From MDS Studies Presented at ASH 5Nplate(R) Data From MDS Studies Presented at ASH 6Nplate(R) Data From MDS Studies Presented at ASH 7Nplate(R) Data From MDS Studies Presented at ASH 8Nplate(R) Data From MDS Studies Presented at ASH 9Nplate(R) Data From MDS Studies Presented at ASH 10European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP Group Account Director 50422 1MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP Group Account Director 50422 2MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP Group Account Director 50422 3Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 1Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 2Lupin Expands Branded Play 50416 1Lupin Expands Branded Play 50416 2Lupin Expands Branded Play 50416 3
... 7 Taligen Therapeutics Inc.,today announced that in ... were presented at the XXII International Complement Workshop ... in,several animal models of complement-mediated diseases., "These ... studies,presented at the conference, reveal the deep expertise ...
... Planned 15 Patient Cohort Enrolled in Stage A of ... Combination With Carboplatin and Paclitaxel -, TUSTIN, Calif., ... a clinical stage biopharmaceutical,company developing monoclonal antibodies for the ... announced that it has completed,enrollment in the first stage ...
Other Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4
(Date:12/6/2009)... new study provides welcome news for patients with a ... , The condition is estimated to impact 62,000 Canadians ... abnormal clot forms in a vein and restricts the ... cases, the clot may detach from its point of ... causing a potentially fatal condition known as a pulmonary ...
(Date:12/6/2009)... Belluck & Fox, LLP says dangerous substances such as asbestos have ... ... New York, NY (PRWEB) December 6, 2009 -- As parents ... alert to reports of recalls due to lead paint or asbestos ... 230,000 children visit hospital emergency rooms each year due to toy-related ...
(Date:12/5/2009)... 5 ,, What: Cuts for a ... in the fight against cancer and other terminal illnesses affecting ... donated to St. Jude Children,s Research Hospital. Guests will enjoy ... delectable and savory Vietnamese restaurant in Falls Church for all ...
(Date:12/5/2009)... Leukemia and myeloproliferative disorders are serious and ... the 51st Annual Meeting of the American Society ... improved diagnostic methods for patients suffering from acute ... leukemia, and myelofibrosis that are based on a ...
(Date:12/5/2009)... Center helps companies develop and test their cleaning processes. The technology ... of industries and solve problems for customers relating to cleaning parts, ... ... 2009 -- Midbrook, Inc , a Jackson, MI-based company, is ...
Breaking Medicine News(10 mins):Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... DALLAS, Oct. 29 Crdentia Corp. (OTC Bulletin,Board: ... it has,completed a private placement of a $5 ... be used for working capital and strategic,initiatives. In ... growth throughout the Sun Belt and enhancing its ...
... problem, most don,t get eyes examined, new ... nationwide survey shows, ... set the clocks back an hour on November 4 and see ... drivers,passengers, and pedestrians about what people may not be seeing while,driving ...
... /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), China,s premier provider ... Ge Li, the company,s Chairman and Chief Executive,Officer ... Year (EOY) China,2007 Award. This prestigious award was ... on October 26 in the China World Hotel, ...
... higher blood pressure and are at greater risk of ... sleep quality and exhibit a smaller nighttime decrease in ... dipping. , This ethnic difference in blood pressure dipping ... risk of hypertension, says Dr. Joel Hughes, Kent State ...
... Docuscan System with Digital Pen Technology Allows Hospitals, ... Capture Patient Information, PHILADELPHIA, Oct. 29 ... Conference, Pearson debuted the,Docuscan Patient Registration system, an ... valuable time and,reducing the chance of data entry ...
... they ,Think About Their Drink, ST. LOUIS, Oct. 29 , WHO: ... About Your Drink Family Challenge ... photo contest by submitting a ... part of a nationwide education campaign, the nation,s ...
Other Medicine News:Health News:Crdentia Announces Completion of $5M Financing 2Health News:Crdentia Announces Completion of $5M Financing 3Health News:Blinded by the Light? Vision Problems and Visual Discomfort Make Driving in the Dark Difficult, Uncomfortable for Most Americans 2Health News:Blinded by the Light? Vision Problems and Visual Discomfort Make Driving in the Dark Difficult, Uncomfortable for Most Americans 3Health News:Blinded by the Light? Vision Problems and Visual Discomfort Make Driving in the Dark Difficult, Uncomfortable for Most Americans 4Health News:WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award 2Health News:WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award 3Health News:Pearson Introduces 'Smart' Technology for Collecting Patient Registration Information 2Health News:Pearson Introduces 'Smart' Technology for Collecting Patient Registration Information 3Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 2Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: